Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Liver Malignancy 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 33Cisplatin 28pembrolizumab 19durvalumab 17Oxaliplatin 16Fluorouracil 16Leucovorin 14Magnetic Resonance Spectroscopy 13Specimen Handling 9Biopsy 9lenvatinib 7Nivolumab 7Capecitabine 7Taxes 6Paclitaxel 6Irinotecan 6fludarabine 5Folfox protocol 5Drug Therapy 5Carboplatin 5Albumin-Bound Paclitaxel 5pemigatinib 4Ipilimumab 4Fluorodeoxyglucose F18 4Floxuridine 4Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Yttrium-90 × 1 year × Clear all
NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡